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Abstract
Background: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protective effects of
soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes were demonstrated using BALB/c mice, the
susceptibility model for this parasite. In order to identify protective fractions, SLA was fractionated by reverse phase
HPLC and five antigenic fractions were obtained.
Methods: F1 fraction was purified from L. (V.) shawi parasite extract by reverse phase HPLC. BALB/c mice were
immunized once a week for two consecutive weeks by subcutaneous routes in the rump, using 25 μg of F1. After
1 and 16 weeks of last immunization, groups were challenged in the footpad with L. (V.) shawi promastigotes.
After 2 months, those same mice were sacrificed and parasite burden, cellular and humoral immune responses
were evaluated.
Results: The F1 fraction induced a high degree of protection associated with an increase in IFN-g, a decrease in
IL-4, increased cell proliferation and activation of CD8
+T lymphocytes. Long-term protection was acquired in F1-
immunized mice, associated with increased CD4
+ central memory T lymphocytes and activation of both CD4
+ and
CD8
+ T cells. In addition, F1-immunized groups showed an increase in IgG2a levels.
Conclusions: The inductor capability of antigens to generate memory lymphocytes that can proliferate and secrete
beneficial cytokines upon infection could be an important factor in the development of vaccine candidates against
American Tegumentary Leishmaniasis.
Keywords: Leishmania (Viannia) shawi, Proteic fraction, Immunization, Cellular immune response, Long-term
protection
Background
Leishmaniasis constitutes a group of diseases ranging
from visceral to cutaneous forms of illness. In the New
World, different species of Leishmania act as agents of
human disease [1,2], such as L. (L.) chagasi or L. (L.)
infantum,w h i c hi st h eo n l ys p e c i e sk n o w nt oi n d u c e
the visceral form of the disease. Tegumentary forms can
be caused by distinct species, which are responsible for
the spectrum of disease ranging from single cutaneous
lesions to anergic diffuse leishmaniasis [3-5]. The con-
trol of tegumentary leishmaniasis in the New World is
difficult due to the natural features of reservoir and vec-
tors, making the elimination of both components hard
to achieve [6]. For these reasons, the development of
prophylactic measures is highly indicated for the control
of leishmaniasis.
An interesting prophylactic measure to limit the epide-
miology of leishmaniasis is the development of vaccines.
The immunogens used to formulate vaccine candidates
can be classified according to their method of formulation:
live parasites, the classic model of leishmanization [7]; first
* Correspondence: felipepassero@yahoo.com.br
1Depto. de Patologia da Faculdade de Medicina da Universidade de São
Paulo, Laboratório de Patologia de Moléstias Infecciosas (LIM-50), São Paulo,
Brazil
Full list of author information is available at the end of the article
Passero et al. Parasites & Vectors 2012, 5:64
http://www.parasitesandvectors.com/content/5/1/64
© 2012 Passero et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.generation vaccines that use crude parasite antigens [8,9];
second generation vaccines that use fractionated, purified
or recombinant antigens [10]; and third generation vac-
cines that use genetic material as the immunogen [11].
Second generation vaccine candidates present good per-
spectives for the development of vaccines, since some
immunosuppressive antigens present in first generation
vaccines can be eliminated through purification [12].
Moreover, second generation vaccines present no risk of
intercalating with the host genetic material, as some DNA
vaccines can do, despite their potential for curing a num-
ber of disorders [13]. Thus, an important class of second
generation vaccine candidates have been purified and ana-
lyzed regarding their protective properties, such as fucose
mannose ligand and antigens released by visceral and
cutaneous strains of Leishmania sp., which induced strong
protection in experimental and natural leishmaniasis
[14-16].
In the New World, at least seven species of Leishmania
affect humans and the most important cutaneous species
are L. (L.) amazonensis and L. (V.) braziliensis [1]. For this
reason, the development of vaccine candidates is impor-
tant to protect people living in endemic areas who are
exposed to vectors and parasites [17]. A series of fractions
and purified antigens have been characterized and used to
achieve protection against L. (L.) amazonensis and L. (V.)
braziliensis [18-20]. Despite their medical and epidemiolo-
gical importance in the New World, other parasite species
that affect humans are rarely studied, such as L. (V.) shawi
and L. (V.) panamensis [21,22]. Some recent studies have
demonstrated that antigens derived from both these spe-
cies were immunogenic and beneficial to experimental
hosts following challenge [23,24]. Species of the Viannia
subgenus can be a useful target for developing cross-pro-
tective vaccine candidates, sin c et h e ya r em o n o p h y l e t i c ,
and thus have homologous antigens with other Leishma-
nia (Viannia) sp. [25], facilitating the development of
cross-protective vaccines. Moreover, in the New World,
the majority of species affecting humans belong to the
Viannia subgenus, thus justifying the search of vaccine
candidates among L. (Viannia) sp. representatives.
In order to identify immunogenic fractions involved in
the protection of BALB/c mice, the soluble leishmanial
antigen (SLA) from L. (V.) shawi was fractionated and the
effect of one proteic fraction (F1) was analyzed regarding
its constitution and the degree of protection induced in
BALB/c mice following an infectious challenge. The main
immunological alterations that occurred in BALB/c mice
were also evaluated.
Methods
Experimental animals
Eight-week-old male BALB⁄c mice obtained from the
Animal Facility of the School of Medicine of São Paulo
University, Brazil, were maintained in our laboratory
during the experiments, in accordance with the institu-
tional guidelines regarding the welfare of experimental
animals and with the approval of the Animal Ethics
Committee of São Paulo University (0280/07).
Parasite
L. (V.) shawi (MHOM/BR/96/M15789) parasite was iso-
lated from a patient with American tegumentary leish-
maniasis in Buriticupu County, State of Maranhão,
Brazil, and identified by monoclonal antibodies and
multilocus enzyme electrophoresis at the Evandro Cha-
gas Institute in Belém, State of Pará, Brazil. The para-
sites maintained in BALB/c mice footpads were isolated
and grown in RPMI-1640 medium (Gibco Invitrogen,
USA) supplemented with 10% heat-inactivated FCS,
0.25 mM HEPES, 10 μg/ml gentamicin and 100 IU/ml
penicillin. On day 6 of culture, promastigote forms were
centrifuged (1,200 g, 10 min) with phosphate buffer sal-
ine solution (PBS, pH 7.4) and used for antigen produc-
tion and mouse infection.
Purification of antigens from L. (V.) shawi promastigotes
Promastigote forms (~10
9 promastigotes) in the station-
ary phase of growth were recovered by centrifugation at
1,200 g for 10 min at 4°C, followed by 3 washes with
phosphate buffered saline (PBS) at 1,200 g for 10 min at
4°C. Lysis buffer (20 mM Tris-HCl; 40 mM NaCl; 10
mM EDTA) was added to the promastigote pellet and
the material was frozen in liquid nitrogen and thawed at
room temperature three times to produce total parasite
extract (AG). Further, AG was centrifuged at 10,000 g
for 1 h at 4°C, the supernatant was collected (SLA), lyo-
philized and applied onto a reverse phase HPLC to pur-
ify the proteic fractions, according to the methodology
described in Toyama et al. (2001) [26]. Briefly, lyophi-
lized SLA (containing 10 mg of proteins) was dissolved
in 250 μl of buffer A (0.1% trifluoroacetic acetic acid,
TFA) and the supernatant was then applied on an analy-
tical reverse phase HPLC column, previously equili-
brated with buffer A for 15 min. The elution of
fractions was conducted using a linear gradient of buffer
B (66.6% Acetonitrile in buffer A) and the chromato-
graphic run was monitored at 280 nm of absorbance for
55 min. The fractions were collected based on their
sharpness and their hydrophilic profile in the elution
buffer. The samples were lyophilized and further solubi-
lized with PBS, sterilized in a 0.22 μm membrane
(Eppendorff, USA) and the protein amounts were esti-
mated through the Bradford method. Lysis buffer was
also applied onto an analytical reverse phase HPLC col-
umn as control sample under the same conditions of
SLA. F1 was submitted to electrophoresis to determine
the presence of proteins [27].
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Purified F1 was reduced, alkylated and submitted to in-gel
digestion with trypsin [28]. An aliquot (4.5 μL) of the
resulting peptide mixture was separated by C18 (100 μm×
100 mm) nanoUPLC (nanoAcquity, Waters) coupled with
a Q-Tof Ultima mass spectrometer (Waters) with nano-
electrospray source at a flow rate of 0.6 mL/min. The gra-
dient was 2-90% acetonitrile in 0.1% formic acid over 45
min. The instrument was operated in the ‘top three’ mode,
in which one MS spectrum was acquired followed by MS/
MS of the top three most-intense peaks detected. The
spectra were acquired using software MassLynx v.4.1 and
the raw data files were converted to a peak list format
(mgf) by the software Mascot Distiller v.2.3.2.0, 2009
(Matrix Science Ldt.) and searched against non-redundant
protein database NCBI nr 2010.09.24 restricted to Leish-
mania (51635 sequences; 31433329 residues) using search
engine MASCOT v.2.3.01 (Matrix Science Ltd.), with car-
bamidomethylation as a fixed modification, oxidation of
methionine as a variable modification, one trypsin missed
cleavage and a tolerance of 0.1 Da for both precursor and
fragment ions.
Immunization scheme and challenge
Male BALB/c mice, eight per group, were immunized with
F1 fraction once a week for two consecutive weeks by sub-
cutaneous route in the rump using 25 μgo fp r o t e i n
[16,24]. Control mice (n = 16) were injected with 50 μlo f
PBS by the same route. One week after the last immuniza-
tion, immunized mice were infected subcutaneously in the
hind footpad with 10
6 promastigote forms of L. (V.) shawi.
Eight mice from the control group received only PBS in
the hind footpad and the remainder were infected using
the same procedure for immunized mice. To investigate
the long-term protection [29] induced by F1, mice were
immunized as described above, and were challenged in the
footpad after 4 months (F1-4 m group). The infection was
monitored weekly for eight weeks by measuring the lesion
size using a dial micrometer and expressed as the differ-
ence in size between the infected and the contra lateral
uninfected footpad. The mice were sacrificed in a CO2
chamber and skin and lymph node fragments were
obtained to determine parasite burden by the limiting-
dilution assay [30]. Fragments of skin from the F1, F1-4 m,
Infected and Healthy groups were processed by usual his-
tological techniques to analyze the inflammatory process.
Evaluation of cellular immune responses
Popliteal lymph nodes from F1, F1-4 m, Infected and
Healthy groups were collected at 8 weeks postinfection
and the cell suspensions (2 × 10
5/well) were cultured
under stimulation with 10 μgo fA Go rF 1f r a c t i o n .A f t e r
72 h, the supernatants were collected and the amounts of
IL-4, IL-12, IFN-g, (BD, USA) and TGF-b (e-Biosciences,
USA) were quantified by sandwich ELISA, in accordance
with the manufacturer’s recommendations, using recom-
binant cytokines as standard. Following supernatant col-
lection, cell proliferation of each group was evaluated as
described by Ahmed et al. (1994) [31]. Briefly, the plates
with cells were washed 3 times with PBS and then 50 μl
of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) at 5 mg/ml in RPMI 1640 was added to
each well. After 4 h, 50 μl of 10% SDS was added to the
wells. The plate was read in an ELISA reader at 595 nm.
Analysis of memory T lymphocytes in immunized mice
Lymph node cells from F1, F1-4 m, Infected and Healthy
groups were adjusted to 8 × 10
5 cell in a 96-well plates
and monoclonal antibodies (BD, USA) anti-mouse CD3ε
(FITC), anti-mouse CD4 L3T4 (PerCP), anti-mouse CD8a
(Alexa Fluor 700), anti-mouse CD45RB (PE) and anti-
mouse CD62L (APC) at a dilution of 1:100 were added to
the cell culture and incubated for 30 min at 4°C. After this
step, the cells were washed three times with MACS buffer
(2 mM EDTA; 0.5% BSA em PBS) and the plate was cen-
trifuged at 1700 rpm for 5 min at 4°C. The cells were fixed
with 100 μl paraformaldehyde 1%, and the sample acquisi-
tions were performed using a FACSCanto cytometer (BD,
USA). To compensate samples, microbeads (BD, USA)
stained with each monoclonal antibody was prepared and
they were injected into the cytometer prior to the samples.
The data were analyzed using FlowJo 7.6.1 (TreeStar,
USA) for Windows. Both CD4
+ and CD8
+ T lymphocyte
were identified in samples, followed by identifica-
tion of CD62L
low and CD62L
high positive subsets. These T
lymphocyte populations were further characterized by
CD45RB marker [32] (Additional file 1: Figure S1).
Analysis of the humoral immune response
The humoral immune response was evaluated by enzyme-
linked immunosorbent assay (ELISA). High-binding plates
(Costar, USA) were coated with 1 μg/well of L. (V.) shawi
SLA, overnight at 4°C. Next, the plates were blocked with
10% of nonfat milk in PBS (2 h at 37°C) to prevent non-
specific binding. Mouse sera (1:50) were added and the
plates were incubated for 1 h at 35°C. After washing, HPR
goat anti-mouse IgG1 and IgG2a (SouthernBiotech, USA)
(1:2000) were used for 1 h at3 5 ° C .A f t e rw a s h i n g ,T M B
was added to each well for 15 min. The reaction was
stopped with 50 μl of 2 N sulfuric acid and the plates were
read at 450 nm in an ELISA reader. Sera from L. shawi
chronically infected mice were also used as positive con-
trols (data not shown). PBS with 0.05% Tween 20 was
used in all washing steps.
Statistical analysis
The results were expressed as the mean ± standard
deviation of three independent experiments and the
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pare lesion size, parasite load and cytokine expression
between the groups. Differences were considered statis-
tically significant at a 5% significance level (p <0 . 0 5 ) .
Statistical analysis was performed using SPSS 17.0 for
Windows software (SPSS Inc. USA).
Results
Purification of F1 fraction and brief summary of mass
spectrometry data
The whole antigen was submitted to reverse phase
HPLC to purify the fraction F1 (Figure 1, black line).
The lysis buffer (control sample) did not interfere in the
purification of F1 fraction (Figure 1, grey line). F1 frac-
tion yield around one percent of SLA.
Due to the important data obtained using the F1 frac-
tion, we considered it essential to identify the proteins
present in this fraction. Mass spectrometry demonstrated
that F1 presented 65 different proteins, 41 with acidic, 24
basic and 4 with a neutral pH. Thirty-two proteins
belonging to F1 of L. (V.) shawi present similarities with
proteins of L. (V.) braziliensis,1 4w i t hp r o t e i n so fL. (L.)
infantum, 11 with proteins of L. major, 7 with proteins of
L. (L.) mexicana and 1 with a protein of L. donovani.
Other proteins had no previous reports in the literature
concerning their functional activities and were consid-
ered hypothetical proteins (Additional file 2: Table S1).
Lesion size, histology and analysis of parasite burden
The infected group presented a progressive increase in
lesion size over time (Figure 2A), while the F1 and F1-4
m-immunized groups showed a decrease in skin lesions,
which was significantly lower than infected mice
between 5 and 8 weeks post-challenge (p < 0.05).
T h eF 1 - i m m u n i z e dg r o u pp r e s e n t e dar e d u c t i o no f
8 7 %i np a r a s i t e si nt h es k i na n d9 2 %i nt h el y m p h
nodes, while in F1-4 m-immunized mice, a reduction of
89.5% in the skin and 95.7% in the lymph nodes was
recorded (Figure 2B).
The skin of the F1 and F1-4 m groups presented focal
mononuclear inflammatory infiltrate with no necrotic
region and macrophages with few parasites (Figure 2C
and 2D, arrows). In contrast, the infected group pre-
sented diffuse inflammatory infiltrate into the epidermis
and dermis, with heavily parasitized mononuclear cells
(Figure 2E).
Figure 1 Soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes was submitted to reverse phase chromatography and F1
proteic fraction were isolated based on their sharpness and hydrophilicity (black line). Lysis buffer also was applied as sample control
(grey line).
Passero et al. Parasites & Vectors 2012, 5:64
http://www.parasitesandvectors.com/content/5/1/64
Page 4 of 10Analysis of cellular immune response
Lymph node cells from the F1 and F1-4 m groups under
stimulation with either AG or F1 fraction produced
greater levels of IFN-g compared with cells from
infected mice (p < 0.05) stimulated with the same anti-
gens (Figure 3A).
In comparison with the infected group, AG-stimu-
lated cells from the F1 and F1-4 m groups presented
diminished production of IL-4 (p < 0.05); however, the
stimulation of cells from the F1 and F1-4 m groups
with F1 fraction led to the increase of this cytokine (p
< 0.05), which was not detected in cells from infected
mice under F1 fraction stimulation (Figure 3B).
Cells from healthy mice produced no significant
amounts of cytokines. Similarly, cells from all groups with
no specific stimulation produced no IL-4 and IFN-g. IL-12
and TGF-b proteins were not detected with or without
specific stimulations.
After stimulation with AG and F1 fraction, cell prolifera-
tions were assayed using MTT (Figure 4). The F1 and F1-4
m groups presented significantly greater proliferation
under any stimuli compared with cells from both infected
and healthy mice (p < 0.05).
Analysis of memory T lymphocytes in immunized mice
The F1-4 m group presented a significant increase (p <
0.05) in CD4
+CD62L
lowCD45RB
low T lymphocytes
Figure 2 Lesion development, parasitism and histopathology of F1, F1-4 m and Infected groups. A–The course of lesions was
accompanied during 8 weeks in all groups. B–Parasitism in skin and lymph nodes of F1, F1- 4 m and Infected groups. C, D, E–Histopathology
of skin from F1, F1-4 m and Infected groups, respectively. Arrows show amastigote inner mononuclear cells. Coloration in HE at 400×
magnification. Bars represent 5 μm. * and ** p < 0.05 indicate that lesion size of F1 and F1-4 m groups significantly differ from infected mice.
†and
††p < 0.05 indicate that parasite burden in the skin and lymph nodes of F1 and F1-4 m group significantly differ from infected mice.
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+T central memory lymphocytes) compared with
infected and healthy groups (Figure 5A). Both the F1
and infected groups presented significant reductions in
the frequencies of CD8
+ T memory central cells
(CD8
+CD62L
lowCD45RB
low).
F1-4 m presented a significant increase in CD3
+CD4
+CD62L
lowCD45RB
high (activated CD4
+ T lymphocytes)
(Figure 5B) compared with infected and healthy mice
(p < 0.05), and both F1 and F1-4 m presented signifi-
cant increases in activated CD8+ T cells (CD3
+CD8
+CD62L
lowCD45RB
high)c o m p a r e dw i t hi n f e c t e da n d
healthy mice.
The frequencies of naïve T CD4
+ and CD8
+ lympho-
cytes (CD3
+CD4
+CD62L
high or CD3
+CD8
+CD62L
high)
were similar between the groups (data not show).
Analysis of humoral immune response
All the experimental groups presented increases in IgG1
anti-Leishmania antibodies compared with healthy mice
(p < 0.05); however, the F1-immunized group presented a
significant reduction in IgG1 anti-Leishmania compared
with infected mice (Figure 6). The levels of IgG2a anti-
Leishmania were increased in both the F1 and F1-4 m
groups compared with infected and healthy mice (p <
0.05).
Discussion
I nt h ep r e s e n ts t u d yt h ea n t i g e n i cf r a c t i o n( F 1 )d e r i v e d
from L. (V.) shawi promastigotes was purified, character-
ized and its protective potential in a murine model of
L. (V.) shawi infection was evaluated. The F1 fraction
obtained seems to provide long-term protection for mice.
Characterization of the F1 fraction revealed its com-
plexity. The fraction was composed of a variety of pro-
teins that had no previously reported function, but these
can be associated with physiological requirements of
L. (V.) shawi. Certain proteins seem to participate in the
physiology and the infective processes of this parasite,
such as a-tubulin, elongation factor 1-a and glucose
transporter (details in Additional file 2: Table S1) and a
few of them had some immunostimulatory properties,
such as dynein [33], chaperonin HSP60 [34] and kinesin
[35]. Dey et al. [36] verified that a DNA vaccine com-
posed of kinesin and esat-6 genes from L. donovani and
Mycobacterium tuberculosis, respectively, presented high
immunogenicity to BALB/c mice as determined by its
potential to induce IL-2 and IFN-g production, indicat-
ing that kinesin protein presented in F1 could partici-
pate in the immunity generation of F1 and F1-4 m-
immunized mice; however, some proteins could be asso-
ciated with the suppression of cellular immune response
due to the diversity of F1. In addition, the F1 fraction
Figure 3 The levels of IFN-g (A) and IL-4 (B) were quantified in supernatant of lymph node cells from F1, F1-4 m and Infected groups.
* and **p < 0.05 indicate that cytokine production from cells stimulated with AG or F1 significantly differs from cytokine production from the
infected group under the same stimulations.
Figure 4 Cell proliferation was assayed in F1, F1-4 m, Infected
and Healthy groups. * and ** p < 0.05 indicate that cellular
proliferation of cells stimulated with AG and F1 significantly differ
from cells from the infected group under the same stimulations.
†
and
†† p < 0.05 indicates that cellular proliferation of cells
stimulated with AG and F1 significantly differ from the Healthy
group under the same stimulations.
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L. (V.) braziliensis. Antigens with previously reported
immunostimulatory properties showed a high degree of
genetic similarities with those of L. (V.) braziliensis (98-
100%). On the other hand, antigens from L. (V.) shawi
presented some degree of genetic heterogenicity (68-
89%) compared with antigens of Leishmania subgenus
representatives (data not shown). These findings suggest
that certain antigens of the F1 fraction could be inter-
esting targets for the development of a cross-protective
vaccine against infections caused by the Viannia subge-
nus due to the high degree of similarity. However, this
proposal needs to be confirmed in future experiments.
In experimental L. (V.) shawi infection, progressive dis-
ease is associated with greater lesion size, strong inflam-
matory processes with necrotic areas and heavily
parasitized mononuclear cells [22,30]. In the F1 fraction,
certain proteins may be protective, since F1-immunized
mice were able to control the infection, as determined by
the smaller lesion size, mild inflammatory processes and,
importantly, they drastically reduced the number of para-
sites in the skin and lymph nodes of mice. These charac-
teristics were reproduced in mice that were challenged 4
months after the last immunization, suggesting that as
well as immunogenicity and protection, the F1 fraction
induced long-term protection.
In fact, lymph node cells from the groups immunized
with the F1 fraction increased the levels of IFN-g and
reduced production of IL-4 following AG stimulation. To
eliminate parasites, it is essential to increase IFN-g levels,
since this cytokine is capable of activating macrophages to
a leishmanicidal state through the production of microbi-
cidal compounds, such as nitric oxide, and upregulate the
expression of MHC [37], permitting elimination of the
Figure 5 Analysis of memory cells in F1, F1-4 m, Infected and Healthy groups.* p < 0.05 indicates statistically significant differences
between the frequencies of CD4
+CD62L
lowCD45RB
low and CD4
+CD62L
lowCD45RB
high T lymphocytes compared with the frequencies of the
infected group. **p < 0.05 indicates statistically significant differences between the frequencies of CD8
+CD62L
lowCD45RB
high T lymphocytes
compared with the frequencies of the infected group.
†p < 0.05 indicates that the frequencies of CD4
+CD62L
lowCD45RB
low and CD4
+CD62L
lowCD45RB
high T lymphocytes significantly differ compared with the frequencies of the healthy group.
††p < 0.05 indicates that the
frequencies of CD8
+CD62L
lowCD45RB
low and CD8
+CD62L
lowCD45RB
high T lymphocytes significantly differ compared with the frequencies of the
infected group.
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antigens to lymphocytes. Concomitantly, a low level of IL-
4 is highly important to achieve resistance, since it can be
viewed as a suppressor and mediator of Th1 and Th2
immune responses, respectively [38]. In addition, some
studies of vaccination using second-generation vaccine
candidates demonstrated that protection was associated
with an increase in IFN-g and a decrease in IL-4 cytokines
in mice [39], indicating that immunogens capable of sti-
mulating this immunological profile could be important
vaccine candidates.
The stimulation of lymph node cells from F1- and F1-4
m-immunized mice with F1 fraction led to an increase in
IFN-g and IL-4 levels. Although IL-4 has been accepted as
inductor of susceptibility in leishmaniasis, some studies
have shown its importance in the generation, proliferation
and maintenance of memory cells in experimental infec-
tions by L. donovani and Plasmodium yoelii [40,41]. In
fact, cells from F1 and F1-4 m showed increased prolifera-
tion compared with cells from infected mice, indicating
that IL-4 could be partly responsible for this activity. In
addition, in nonimmunized mice, cell proliferation did not
occur, suggesting immune suppression caused by high
parasitism, like that observed for L. donovani and L. major
species [42,43]. Besides the role of IFN-g in the activation
of infected cells, it also could play an important role in T
lymphocyte proliferation [44].
After their encounter with antigens, lymphocytes are
activated and proliferate, and after their clearance by regu-
latory mechanisms, the quantity of lymphocytes decreases,
resulting in a small fraction of surviving memory cells that
readily proliferate following a new encounter with the
antigen [45]. In order to evaluate the frequencies of mem-
ory T cells in immunized mice, T lymphocytes were phe-
notyped with the markers CD62L and CD45RB. CD62L is
an adhesion molecule associated with the activation and
circulation of activated lymphocytes [46,47]. CD45RB is an
important molecule associated with TCR activation [48]
and its expression is reduced following T lymphocyte acti-
vation. For these reasons, it is possible to assume that T
lymphocytes presenting the phenotype CD62L
lowCD45R-
B
low are central memory cells and CD62L
lowCD45RB
high
are activated T cells [32,49].I nt h i ss t u d y ,t h eF 1g r o u p
presented a low frequency of central memory CD8
+ T
cells and a high frequency of activated CD8
+ Tl y m p h o -
cytes, a reduction that could be associated with the differ-
entiation of CD8
+CD62L
lowCD45RB
low toward an
activated phenotype. Similar results were viewed in the
F1-4 m group; however, without the decrease in the fre-
quency of central memory CD8
+ T cells. This activated
phenotype of CD8
+T lymphocytes should allow traffic
between homing lymphoid organs to the site of infection,
where this cell population can eliminate infected cells,
since the main characteristic of CD8
+T lymphocyte is to
eliminate the target cell by cytotoxicity [50,51]. Moreover,
vaccination studies have stated that CD8
+T cells activated
by immunogens are primordial in the resistance against
intracellular infections, establishing long-term immunity
[29,52]. Thus, immunization with the F1 fraction should
activate CD8
+T cells, leading to resistance against L. (V.)
shawi infection.
T h eF 1 - 4mg r o u pa l s os h o w e da ni n c r e a s ei nb o t h
central and activated CD4
+ T lymphocytes, which was
not observed in the F1 group. This fact can be associated
with a high frequency of CD8
+ T lymphocytes in F1-4 m,
since activation of high numbers of CD8
+T cells can also
activate CD4
+T lymphocytes, increasing the production
of IFN-g [53], which was observed in stimulated cells of
F1-4 m mice.
T h ei n c r e a s ei nI L - 4a n dI F N - g can have direct conse-
quences in elevating IgG1 and IgG2a, respectively [54].
These isotypes seem to have a direct correlation between
susceptibility and resistance in experimental leishmaniasis,
since IgG1 is linked to humoral immune response, while
IgG2a is associated with the cellular immune response
[55] and parasite destruction, which taken together, sup-
port the present results in which F1-immunized mice tend
towards resistance induced by immunization with the F1
fraction, while the infected group tends towards
susceptibility.
Conclusions
Analysis of our results indicates that the F1 fraction
induces a beneficial response in BALB/c mice. The anti-
genic fraction favored increased production of IFN-g,
which has been associated with resistance against infec-
tion. Moreover, the long-term protection observed in
immunized mice could be associated with both central
memory and activated CD4
+ and CD8
+ T lymphocytes.
The results presented herein suggest that resistance
Figure 6 Humoral immune response in F1, F1-4 m, Infected
and Healthy mice. * and **p < 0.05 indicate that IgG1 and IgG2a
anti-Leishmania significantly differ from the infected group,
† and
††p < 0.05 indicate that IgG1 and IgG2a anti-Leishmania significantly
differ from the healthy group.
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Page 8 of 10against L. (V.) shawi infection can occur through activa-
tion of both CD4
+ and CD8
+ T lymphocytes. Antigens
capable of inducing this immunological profile could be
important targets in the development of vaccine candi-
dates against American Tegumentary Leishmaniasis.
Additional material
Additional file 1: Figure S1. Flow cytometry strategy used to analyze
cell populations. CD4+ and CD8 + T lymphocytes were identified,
followed by their characterization of CD62L low and high populations.
The levels of expression of CD45RB were analyzed in the population with
high and low expression of the markers CD62L.
Additional file 2: Table S1. Proteins detected in F1 antigen purified
through reverse phase HPLC.
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